Suggestion on Improvement of Tax System for Fostering and Supporting the Bio－Pharmaceutical Industry
Asian Tax Journal Vol. 22 No. 1 (2021), pp. 9-31
Abstract
This study suggests the improvement of tax system in order to foster and support the bio－pharmaceutical industry. Specifically, we focus on whether the existing tax benefits are designed to properly reflect the fiercely changing international environment and the rapidly changing international environment, especially in the bio－pharmaceutical industry. We find that current tax benefits are provided primarily to the costs incurred in the R&D stage. However, if related revenue generated as a result of R&D is subject to the lower tax rate, this also increases the after－tax profit of R&D activities, which in turn increases the R&D investment return. From this perspective, in many foreign countries, tax incentives are provided through the introduction of the patent box system to profit－generating activities through R&D activities. Notably, there are no particular restrictions on its application, provided that the profit－making activities are proved as the products of R&D activities. Accordingly, this study suggests that the tax exemption for technology transfer presented in Article 12, Paragraph 3 of the Tax Exemption Restriction Act be extended to large corporations. We find that such a policy would create a front－to－back chain effect through organic relations with other industries, which would have a significant positive economic effect. We believe that this improvement in tax support will provide a foundation for domestic bio pharmaceutical firms to gain competitiveness in the international pharmaceutical bio market and revitalize the domestic industry to grow national competitiveness.
Keywords
- bio－pharmaceutical industry
- tax system
- R&D
- patent box
- tax exemption
Related Articles
The Effects of In－process R&D Information on Value Relevance of Capitalized R&D in Bio－Pharmaceutical Industries
23(5) 139-160
The Effects of R&D Capitalization and Accounting Error Correction on Value Relevance：Focused on the Theme Supervision of Bio－Pharm Companies
22(4) 67-95
The Effects of R&D Capitalization and Accounting Error Correction on Value Relevance：Focused on the Theme Supervision of Bio－Pharm Companies
22(1) 67-87
The Value Relevance of R&D Expenditures in Biotechnology Special Listing Firms
25(4) 77-102
Economic Policy Uncertainty and Investment Efficiency
22(6) 45-74